Figure 1From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study Kaplan–Meier curves indicating cumulative hazard for the development of efavirenz-based highly active antiretroviral therapy associated neuropsychiatric symptoms between the different CYP2B6 genotype groups during 12 weeks in Ugandan HIV patients. Back to article page